Literature DB >> 33044435

Increased Duration of Exercise Decreases Rate of Nonresponse to Exercise but May Not Decrease Risk for Cancer Mortality.

Dan Lin1, Melanie Potiaumpai, Kathryn Schmitz, Kathleen Sturgeon.   

Abstract

INTRODUCTION: Previous studies have observed an inverse relationship between exercise and breast cancer risk. However, there is interindividual variability in response to exercise training interventions. We investigated whether increasing the dose of aerobic exercise (150 or 300 min·wk-1), while keeping intensity of exercise constant (70%-80% HRmax), decreases the number of exercise nonresponders and further decreases associated risk for cancer mortality in our study population of women genetically predisposed for breast cancer.
METHODS: Healthy premenopausal women at elevated risk of breast cancer were randomized into control (<75 min·wk-1, n = 47), low-dose exercise (150 min·wk-1, n = 39), and high-dose exercise groups (300 min·wk-1, n = 39) for approximately 6 months. We assessed 1) clinical effectiveness (CE), defined as an improvement in predicted V˙O2max of ≥1 mL·kg-1·min-1, and twice the typical error (2× TE) of V˙O2max as thresholds to classify exercise "nonresponders"; 2) CE and 2× TE relative to exercise adherence levels; and 3) related changes in V˙O2max to predicted cancer mortality risk.
RESULTS: After our 6-month intervention, we observed that 23.5% of women in the low-dose group and 5.6% of women in the high-dose group were clinical nonresponders (P = 0.04). Clinical nonresponder status was independent of adherence level. Associated reduction in risk for cancer mortality was observed among 87.2% of women in the low-dose group and 94.9% in the high-dose group (P = 0.43).
CONCLUSION: Increasing volume (not intensity) of exercise via time spent exercising significantly decreases the number of "nonresponders." True nonresponders were observed as some women did not improve their fitness capacity despite high exercise adherence levels. Lastly, it appears 150 min·wk-1 is sufficient to decrease the predicted risk of cancer mortality.
Copyright © 2020 by the American College of Sports Medicine.

Entities:  

Mesh:

Year:  2021        PMID: 33044435      PMCID: PMC8026778          DOI: 10.1249/MSS.0000000000002539

Source DB:  PubMed          Journal:  Med Sci Sports Exerc        ISSN: 0195-9131


  47 in total

1.  Meeting the physical activity guidelines and survival after breast cancer: findings from the after breast cancer pooling project.

Authors:  Jeannette M Beasley; Marilyn L Kwan; Wendy Y Chen; Erin K Weltzien; Candyce H Kroenke; Wei Lu; Sarah J Nechuta; Lisa Cadmus-Bertram; Ruth E Patterson; Barbara Sternfeld; Xiao-Ou Shu; John P Pierce; Bette J Caan
Journal:  Breast Cancer Res Treat       Date:  2011-09-21       Impact factor: 4.872

2.  Randomized controlled trial of exercise training in postmenopausal breast cancer survivors: cardiopulmonary and quality of life outcomes.

Authors:  Kerry S Courneya; John R Mackey; Gordon J Bell; Lee W Jones; Catherine J Field; Adrian S Fairey
Journal:  J Clin Oncol       Date:  2003-05-01       Impact factor: 44.544

3.  Modest increase in peak VO2 is related to better clinical outcomes in chronic heart failure patients: results from heart failure and a controlled trial to investigate outcomes of exercise training.

Authors:  Ann M Swank; John Horton; Jerome L Fleg; Gregg C Fonarow; Steven Keteyian; Lee Goldberg; Gene Wolfel; Eileen M Handberg; Dan Bensimhon; Marie-Christine Illiou; Marianne Vest; Greg Ewald; Gordon Blackburn; Eric Leifer; Lawton Cooper; William E Kraus
Journal:  Circ Heart Fail       Date:  2012-07-06       Impact factor: 8.790

Review 4.  Incidence of nonresponse and individual patterns of response following sprint interval training.

Authors:  Brendon J Gurd; Matthew D Giles; Jacob T Bonafiglia; James P Raleigh; John C Boyd; Jasmin K Ma; Jason G E Zelt; Trisha D Scribbans
Journal:  Appl Physiol Nutr Metab       Date:  2015-11-03       Impact factor: 2.665

5.  Epidemiology, Incidence and Mortality of Breast Cancer in Asia.

Authors:  Mahshid Ghoncheh; Zohre Momenimovahed; Hamid Salehiniya
Journal:  Asian Pac J Cancer Prev       Date:  2016

6.  Incidence and Mortality and Epidemiology of Breast Cancer in the World.

Authors:  Mahshid Ghoncheh; Zahra Pournamdar; Hamid Salehiniya
Journal:  Asian Pac J Cancer Prev       Date:  2016

7.  Dose-dependent effect of aerobic exercise on inflammatory biomarkers in a randomized controlled trial of women at high risk of breast cancer.

Authors:  Jeremy S Haley; Elizabeth A Hibler; Shouhao Zhou; Kathryn H Schmitz; Kathleen M Sturgeon
Journal:  Cancer       Date:  2019-09-30       Impact factor: 6.860

8.  Physical activity and the risk of breast cancer.

Authors:  I Thune; T Brenn; E Lund; M Gaard
Journal:  N Engl J Med       Date:  1997-05-01       Impact factor: 91.245

9.  Breast cancer in developing countries: opportunities for improved survival.

Authors:  Lawrence N Shulman; Walter Willett; Amy Sievers; Felicia M Knaul
Journal:  J Oncol       Date:  2010-12-29       Impact factor: 4.375

10.  Inter-Individual Variability in the Adaptive Responses to Endurance and Sprint Interval Training: A Randomized Crossover Study.

Authors:  Jacob T Bonafiglia; Mario P Rotundo; Jonathan P Whittall; Trisha D Scribbans; Ryan B Graham; Brendon J Gurd
Journal:  PLoS One       Date:  2016-12-09       Impact factor: 3.240

View more
  2 in total

1.  Exercise duration: Independent effects on acute physiologic responses and the need for an individualized prescription.

Authors:  Gerhard Tschakert; Tanja Handl; Lena Weiner; Philipp Birnbaumer; Alexander Mueller; Werner Groeschl; Peter Hofmann
Journal:  Physiol Rep       Date:  2022-02

2.  Effect of steady-state aerobic exercise intensity and duration on the relationship between reserves of heart rate and oxygen uptake.

Authors:  Carlo Ferri Marini; Ario Federici; James S Skinner; Giovanni Piccoli; Vilberto Stocchi; Luca Zoffoli; Luca Correale; Stefano Dell'Anna; Carlo Alberto Naldini; Matteo Vandoni; Francesco Lucertini
Journal:  PeerJ       Date:  2022-04-25       Impact factor: 3.061

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.